For Hepatitis C treatment, the approval of interferon-free direct-acting antivirals (DAAs) brought considerable improvements in efficacy, safety, and tolerability compared to existing regimens, while also generating public debate about their costs and associated long-term value. In this report, we estimate the U.S. national and per-patient net cost impact of HCV treatment with DAAs on HCV-related medical costs over a 10-year period (from 2021 to 2030). We estimate a national net savings of $49.2 billion over 10 years.

This paper was commissioned by: Gilead Sciences, Inc.